Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aceclidine/tropicamide - LENZ Therapeutics

Next Previous
Drug Profile

Aceclidine/tropicamide - LENZ Therapeutics

Alternative Names: PRX 100; Tropicamide/aceclidine

Latest Information Update: 25 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Presbyopia Therapies
  • Developer LENZ Therapeutics
  • Class Azabicyclo compounds; Eye disorder therapies; Pyridines
  • Mechanism of Action Adrenergic receptor agonists; Cholinergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Presbyopia

Most Recent Events

  • 17 Jun 2021 Presbyopia Therapies is now called LENZ Therapeutics
  • 17 Jun 2021 LENZ Therapeutics announces intention to submit NDA to the US FDA for Presbyopia
  • 30 Jul 2018 Efficacy and safety data from a phase IIb trial in Presbyopia released by Presbyopia Therapies (NCT03201562)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top